InVivo Biosystems provides an end‑to‑end preclinical platform that uses CRISPR‑engineered C. elegans and zebrafish to generate whole‑organism efficacy, toxicity, and mechanism‑of‑action data within weeks. The RapidGen™ system combines high‑throughput phenotyping, multi‑omics profiling, and AI‑driven data integration, while its CRO services deliver scalable assays including oncology xenografts and humanized models for pharmaceutical and academic users.
Funding
Funding not disclosed
NIFounders
Product
Problem
Preclinical drug discovery often relies on slow, costly rodent studies that provide limited translational insight, creating bottlenecks in efficacy, toxicity, and mechanism‑of‑action assessment for pharmaceutical, biotech, and academic programs.
Solution
InVivo Biosystems delivers an end‑to‑end preclinical platform that accelerates target‑to‑validation timelines by using CRISPR‑engineered *C. elegans* and zebrafish models. The RapidGen™ platform generates whole‑organism data—including behavior, morphology, transcriptomics, proteomics, and multi‑omics readouts—within weeks, enabling rapid decision‑making. Integrated AI pipelines prioritize high‑potential leads, while a suite of CRO services (efficacy, toxicity, neurotoxicity, aging, oncology xenografts, and humanized models) provides scalable, decision‑ready datasets for downstream development.
Target Audience
Primary customers are pharmaceutical, biotechnology, and nutraceutical companies, as well as academic research institutions, that require fast, biologically relevant preclinical data to de‑risk drug development and support regulatory submissions.
Features
- Proprietary CRISPR workflows (Crispants, MIC‑Drop multiplex editing, Tol2 transgenesis) for knockout, knock‑in, point‑mutation, and humanized gene insertion in zebrafish and *C. elegans*.
- Custom genome‑edited animal models tailored to specific genes, disease pathways, or patient‑derived variants.
- RapidGen™ platform delivers high‑throughput whole‑organism phenotyping (behavioral tracking, morphological imaging, multi‑omics profiling) in a matter of weeks.
- AI‑driven data integration and prioritization that highlights efficacy signals, safety flags, and mechanism‑of‑action insights.
- Comprehensive CRO assay portfolio: compound efficacy, toxicity, neurotoxicity, mitochondrial function, vitality, antioxidant capacity, microbiome, and aging studies.
- ZTX® Oncology platform provides rapid zebrafish tumor xenografts for cancer drug and immunotherapy screening, reducing study time from months to days.
- Humanized model services enable whole‑gene or point‑mutation humanization for direct translation of human genetic variants.
- Secure cloud‑based analytics with downloadable reports and API access for seamless integration into client workflows.